Successful treatment with sorafenib in patients with advanced hepatocellular carcinoma: clinical case

Multi-kinase inhibitor sorafenib is the only one drug which increases life time in patients with advanced hepatocellular carcinoma (HCC). Results from the SHARP trial showed that median progression-free survival was less than 5 months. However, it is possible to achieve strong treatment effect for s...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Yu V Bisovskaya, V V Breder, B M Medvedeva, V A Gorbunova
Format: Artigo
Sprache:Russo
Veröffentlicht: IP Habib O.N. 2014-06-01
Schriftenreihe:Современная онкология
Schlagworte:
hepatocellular carcinoma
sorafenib
chronic hepatitis b
lamivudine
Online Zugang:https://modernonco.orscience.ru/1815-1434/article/view/26969
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge